• Emma L O'Dowd, Richard W Lee, Ahsan R Akram, Emily C Bartlett, Stephen H Bradley, Kate Brain, CallisterMatthew E JMEJLeeds Teaching Hospitals NHS Trust, Leeds, UK., Yan Chen, Anand Devaraj, Sinan R Eccles, John K Field, Jesme Fox, Seamus Grundy, Sam M Janes, Martin Ledson, Melanie MacKean, Anne Mackie, Kieran G McManus, Rachael L Murray, Arjun Nair, Samantha L Quaife, Robert Rintoul, Anne Stevenson, Yvonne Summers, Louise S Wilkinson, Richard Booton, David R Baldwin, and Philip Crosbie.
• Nottingham University Hospitals NHS Trust, Nottingham, UK.
• Lancet Oncol. 2023 May 1; 24 (5): e207e218e207-e218.

AbstractLung cancer screening with low-dose CT was recommended by the UK National Screening Committee (UKNSC) in September, 2022, on the basis of data from trials showing a reduction in lung cancer mortality. These trials provide sufficient evidence to show clinical efficacy, but further work is needed to prove deliverability in preparation for a national roll-out of the first major targeted screening programme. The UK has been world leading in addressing logistical issues with lung cancer screening through clinical trials, implementation pilots, and the National Health Service (NHS) England Targeted Lung Health Check Programme. In this Policy Review, we describe the consensus reached by a multiprofessional group of experts in lung cancer screening on the key requirements and priorities for effective implementation of a programme. We summarise the output from a round-table meeting of clinicians, behavioural scientists, stakeholder organisations, and representatives from NHS England, the UKNSC, and the four UK nations. This Policy Review will be an important tool in the ongoing expansion and evolution of an already successful programme, and provides a summary of UK expert opinion for consideration by those organising and delivering lung cancer screenings in other countries.Copyright © 2023 Elsevier Ltd. All rights reserved.

9 keywords...

hide…